Roche's Otu Zumab Monoclonal Antibody Injection is proposed to be included in the priority review in China, suitable for primary membranous nephropathy.

The National Medical Products Administration's drug evaluation center website announced that Roche's application for the priority review of the injection of Atezolizumab is under consideration, which is intended for the treatment of adult patients with primary membranous nephropathy.